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Abstract
Silybum marianum is a medicinal plant that has long been used as hepatoprotective remedy. It has been used for the treatment of
numerous liver disorders characterized by functional impairment or degenerative necrosis. Its hepatoprotective activity is unique
and acts in different ways, including antioxidant and anti-inflammatory activities, cell permeability regulator and membrane sta-
bilizer, stimulation of liver regeneration and inhibition of deposition in collagen fibers, which may lead to cirrhosis. Most of
documented data with Silybum marianum are about liver disorders; however, recently several beneficial properties on a wide
variety of other disorders such as renal protection, hypolipidemic and anti-atherosclerosis activities, cardiovascular protection,
prevention of insulin resistance, especially in cirrhotic patients, cancer, and Alzheimer prevention. It is also used as a food remedy.
This review article aims to present different aspects of Silybum marianum, especially the data in recently published articles about its
effects on different diseases, apart from presenting the aspects of its hepatoprotection.
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Silybum marianum is a medicinal plant whose therapeutic his-
tory dates back to 2000 years ago and was used as a hepatopro-
tective medication to treat jaundice and enlarged liver and
spleen. Originally, Silybum marianum was a native of Asia and
Southern Europe, but now it is found throughout the world.1 The
Food & Drug Administration in Germany has proposed this
medicinal plant to treat digestive disorders, intoxication, and
alcoholic liver and as a complement drug to treat enlarged liver.2
Numerous experimental and clinical studies have documen-
ted that Silybum marianum with its antioxidant activity and
other liver protective properties is a unique hepatoprotective
agent. Silymarin is the main component of Silybum marianum
that has been documented to be highly hepatoprotective. It has
been used for the treatment of numerous liver disorders charac-
terized by functional impairment or degenerative necrosis.
Although its mechanisms of action is not fully understood, it
seems that it acts in different ways, including antioxidant and
anti-inflammatory activities, cell permeability regulator and
membrane stabilizer, stimulating liver regeneration and inhibit-
ing deposition of collagen fibers, which may lead to cirrhosis.
Silybum marianum and its major flavonoid, silymarin, are
effective and well-tolerated antidotes for use against hepato-
toxics, especially psychotropic drugs and the toxic agents pro-
duced by Amanita phalloide.3
Most of documented data about Silybum marianum are
about liver disorders; however, it has beneficial property on a
wide variety of other disorders such as hypoglycemic activity
and reducing insulin resistance in patients with type 2 diabetes
mellitus and its complications.4,5 Silymarin is also able to pro-
tect kidneys against nephrotoxic agents.6 The hepatoprotective
effects of Silybum marianum have been well documented.
However, recent researches have considered it as a key for all
diseases. It is also used as a food remedy. This review article
aims to present different aspects of Silybum marianum, espe-
cially the data in recently published articles about its effects
on different diseases, apart from presenting the aspects of its
hepatoprotection.6
Botany and Morphology
Silybum marianum is of Asteriaceae family and has various
other names including milk thistle, Marian thistle, Mary thistle,
Mary’s thistle, Saint Mary’s thistle, Blessed milk thistle, Med-
iterranean milk thistle, variegated thistle, Cardus marianus,
and Scotch thistle. Silybum marianum has shiny pale green
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leaves and red to purple flowers with white veins. In Persian
and Arabic countries, it is called Mary thiqhal.7
Silybum marianum is a biennale, glabrous, pale green, spi-
nescent plant with straight stems. Leaves of this plant are big
and have white spots around the veins. It has several pinnate
parts as triangular-ovary parts. Silybum marianum has simple
or a little branched or relatively thick branches that terminate
to a green mass and with longitudinal rakes. It grows up to
200 cm in height, with the stem of cottony, having an overall
conical shape. Its leaves are oblong to lanceolate, and the stem
is usually hollow. Silybum marianum is either lobate or pinnate,
with spiny edges and hairless, shiny green, with milk-white
veins. The flower heads of this plant are up to 12 cm long and
wide, with red-purple color (Figure 1).7
Growth Regions
This plant grows in European, Asian, and American countries. In
Iran, it is distributed widely in Noode, Kelardasht, Poshtkooh,
Hezar Valley, Moghan, Poshtkooh, Gonbad-e Ka¯vus, Gorgan,
and Mollathani in Ahvaz, as well as Shoush, Hamidiyeh,
Ramhormoz, Izeh and Kazeroun in other regions of Iran.7
Chemical Compounds
The seeds of this plant contain many compounds such as sily-
bin, silibinin A and B, silicristin, silidianin, apigenin, dehydro-
silybin, deoxysilyn cristin, deoxysilyn dianin, among other.
Extract of dried seed of this plant contains up to 4% silymarin.
Silymarin is a combination of flavonoids such as silibinin A
and B, silidianin, silicristin, and dihydroxysilibin.8,9 Other fla-
vonolignans present in extract of this plant include sylandrin,
silybinom, silyhermin, and myristic, palmitic, and stearic acids,
which may have hepatoprotective properties.4 In addition,
dried seeds of the plant contain up to 20% oil without medicinal
properties.7
Silymarin is readily absorbed from the gastrointestinal tract
and then reaches its maximum blood concentration after 2 to 4
hours. Its half-life excretion is 6 hours. Eighty percent of this
drug is excreted from the bile. Bioavailability of this drug
depends on the type of formulation. Sylibin is the most effec-
tive antioxidant and hepatoprotective substance present in sily-
marin, and its concentration in bile is 60 times more than the
other components.2
Pharmacology and Therapeutic Effects
Various beneficial effects of Silybum marianum or its deriva-
tives have been reported including hepatoprotection, renal
protection, hypolipidemic and anti-atherosclerosis activities,
cardiovascular protection, prevention of insulin resistance,
especially in cirrhotic patients, cancer, and Alzheimer preven-
tion. Silymarin in the traditional medicine is consumed in
European countries to treat different types of diseases and
liver disorders.10,11
Liver Diseases
The uses of Silybum marianum as hepatoprotective dates back
to 2000 years ago. Different clinical and laboratory studies
have also documented that silymarin protects the liver against
toxicities resulting from various toxins such as carbon tetra-
chloride, acetaminophen, and tetrachloromethane.7
It has been reported that silymarin provides the hepatopro-
tective effect by different mechanisms including antioxidant
activity and scavenging free radicals, increase of cellular glu-
tathione concentration, stimulation of DNA polymerase, and
stabilization of hepatocellular membrane.7
Numerous studies have strongly suggested that the hepato-
protective effects of silymarin are mainly due to its antioxidant
activity and free radical scavenging property. This effect is
reflected by glutathione modulation and the membrane stabili-
zation that it produces.12
Stimulation of DNA polymerase by silymarin results in
increase in the synthesis of ribosomal RNA and reconstruction
of liver cells. Increase of cellular glutamine concentration sta-
bilizes superoxide dismutase and glutathione peroxidase. Sily-
marin decreases the enlarged liver by inhibiting 5-lipoxygenase
cycle and inhibiting production of leukotrienes and free radi-
cals in Kupffer cells of liver. Moreover, silybin in the mouse’s
hepatocyte cells inhibits production of peroxidation lipid and
cellular damage.13
Actually the effect of silymarin on cellular permeability is
associated with alterations of membrane lipids including cho-
lesterol and phospholipids. Silymarin also act on other lipid
compartments in the liver that may influence the uptake and
secretion of lipoproteins.14
Data on the influence of silymarin on triglyceride metabo-
lism in the liver are scanty. It is known that in rats silibinin
is able to partly antagonize the increase in total lipids and tri-
glycerides produced in the liver by carbon tetrachloride and,
probably, to activate fatty acid b-oxidation. It has also been
suggested that silymarin may diminish triglyceride synthesis
in the liver.15
Figure 1. Silybum marianum.
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Lette´ron et al studied the mechanisms of action of silymarin
that provide protection against lipid peroxidation and the hepa-
totoxicity of carbon tetrachloride in mice, and they came to the
conclusion that silymarin works by reducing metabolic activa-
tion by carbon tetrachloride and by acting as an antioxidant that
prevents chain rupture.16
Other authors have shown that silymarin affords hepatopro-
tection against specific injury induced by microcystin (a hepa-
totoxin), paracetamol, halothane, and alloxan in several
experimental models.17
Different researchers on live animals suggest that silymarin
protects liver cells against different types of diseases including
viruses, chemical substances, and natural toxic substances. Pre-
treatment of laboratory animals with silymarin protects them
against intoxication from Amanita muscaria. Administration
of silybin (50 mg/kg) in dogs has protected them against the
intoxication resulting from a lethal dose of Amanita muscaria
even after 40 hours after administration of silybin.18 Moreover,
pretreatment of laboratory animals with silymarin inhibits
occurrence of liver intoxication and production of peroxidation
lipid resulting from administration of halothane, thallium tetra-
chloride, carbon tetrachloride, and acetaminophen in these ani-
mals significantly.19 Administration of silymarin or silybin to
rats inhibited the activity of the liver enzymes including g-glu-
tamyl transpeptidase, alanine transaminase, and aspartate trans-
aminase, indicating inhibition of hepatotoxicity resulting by the
alcohol effect.20 Silymarin inhibits alcoholic liver resulting
from biliary atresia in rat.21
Clinical researches indicate that consumption of 120 mg
silybin twice a week for 2 months decreased aspartate transa-
minase and alanine transaminase levels in blood serum of
patients with liver diseases.20 In a study that was conducted
on 2637 patients with chronic liver disorders, administration
of silymarin extract for 8 weeks caused significant decrease
in the amount of liver enzyme in 88% of patients. Minor side
effects of the drug were observed only in less than 1% of
patients.22
Silymarin is also used in the treatment of intoxication result-
ing from Amanita muscaria. This treatment decreased morality
up to 80% in patients.18
Administration of intravenous silybin (20-50 mg/kg/day for
3-4 days) inhibited liver damage completely up to 48 hours after
intoxication with Amanita muscaria. In a study conducted on
250 people intoxicated by Amanita muscaria, 46 deaths were
reported in the nontreated group. However, no mortality was
observed in the group comprising 16 individuals who received
silybin.23 In another study, 18 people who had been poisoned
with Amanita muscaria were treated with silybin. The results
revealed that only one person who took Amanita mushroom to
commit suicide and was not treated for 60 hours had died.24
Other authors have shown that silymarin affords hepatopro-
tection against specific injury induced by microcystin (a hepa-
totoxin), paracetamol, halothane, and alloxan in several
experimental models.25
Administration of silymarin in the treatment of alcohol-
induced liver disease indicates contradictory results. A multiple
controlled double-blind study conducted on 300 patients
with alcohol-induced liver disease showed that silymarin
(420 mg/day) led to significant reduction in enzyme levels and
liver histology evaluation following 4 weeks.26 An additional
study was conducted on 170 patients with alcohol-induced cir-
rhosis who were administered silymarin for a period of 4 years.
The result showed reduction in mortality when compared with
the control group.27 Inversely, in a double-blind study of
administration of silymarin at 280 and 150 mg doses (3 times
daily) on patients with cirrhosis of the liver did not reduce
mortality compared with the control group.28 In another
investigation performed on 116 people with alcohol-induced
hepatitis, the use of 420 mg/day silymarin for 3 months
appeared to show no significant improvement compared with
control group; however, 46% of the patients were able to stop
drinking alcohol.29
It is known that silibinin is capable of neutralizing 2
effects of ethanol in rats: the reduction in labeled glycerol
incorporation into isolated hepatocytes lipids and the inhibi-
tion of phospholipid synthesis.30 In addition, silibinin stimu-
lates synthesis of phosphatidylcholine and increases
cholinephosphate cytidylyltransferase activity in rat liver.31
It is well established that silymarin acts as an antioxidant,
preventing chain rupture and reducing metabolic activation
by carbon tetrachloride.15,32
Administration of silymarin demonstrates contradictory
results in patients with hepatitis. A double-blind investigation
was done on 20 patients with active chronic hepatitis who were
treated by 240 mg silipide twice a day for a week, and the
g-glutamyl transpeptidase level reduced significantly when
compared with the control group.6 Another examination
assessed 157 patients with viral hepatitis. Twenty-nine patients
were treated with silymarin (140 mg, 3 times a day) while 28
received placebo. The results showed significant reduction in
bilirubin content and aspartate transaminase and alanine trans-
aminase levels in the group under treatment with silymarin
when compared with that of the control group.33 In contrast,
silymarin did not improve diseases in an examination on 151
patients with viral hepatitis.34
Another mechanism by which silymarin acts against liver
injury is by stimulation of liver tissue regeneration, which is
done by increase in protein synthesis. Silibinin, apart from
increasing protein synthesis, causes an increase in the forma-
tion of ribosomes and in DNA synthesis. However, the increase
in protein synthesis is induced only in injured livers and not in
healthy livers. Silibinin stimulates protein synthesis in the liver
probably by physiological regulation of RNA polymerase I and
stimulates the formation of ribosomes.35
Silymarin has been shown to inhibit the hepatic cytochrome
P450 (CYP) detoxification system. Silibinin is able to inhibit
numerous hepatic CYP enzyme activities. This effect might
explain the hepatoprotective properties of silymarin against the
intoxication due to Amanita phalloides. The toxin of Amanita
phalloides that becomes lethal for hepatocytes is activated by
the CYP system. Therefore, inhibition of toxin bioactivation
contributes to the limitation of its toxic effects. Furthermore,
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silymarin can contribute toward protection against free radicals
generated by enzymes of the CYP system.36
One of the most effective property of silymarin is its ability
to inhibit cellular permeability, which is associated with
quantitative and qualitative alterations in membrane lipids.37
This suggests that silymarin may influence lipoprotein secre-
tion and uptake. In this regard, silymarin and silibinin have
been shown to reduce the turnover and synthesis of phospho-
lipids in the rat liver. Moreover, silibinin has been shown to
reduce labeled glycerol incorporation into lipids of isolated
hepatocytes and also neutralize the inhibition of phospholipid
synthesis.38
Furthermore, silibinin is able to stimulate phosphatidylcho-
line synthesis and increase the activity of cholinephosphate
cytidylyltransferase in rat liver.31
It should be noted that data on the effect of silymarin on tri-
glyceride metabolism in the liver are scanty. Silibinin partly
antagonizes the increase in triglyceride and total lipids pro-
duced in the liver by carbon tetrachloride. It may also diminish
triglyceride synthesis in the liver.25
Silymarin is able to provide protection against hepatotoxi-
city of carbon tetrachloride and lipid peroxidation. Silymarin
has also been shown in several experimental models to have
hepatoprotection against injury induced by paracetamol,
halothane, alloxan, and microcystin (a hepatotoxin).25,39
Hypoglycemic Activity
Silymarin has been shown to reduce the plasma levels of cho-
lesterol and low-density lipoprotein in hyperlipidemic animals.
It also reduces phospholipid levels, especially those transported
in low-density lipoprotein.25
Laboratory studies show that silymarin led to improved low-
density lipoprotein excretion and reduced cholesterol synthesis
in liver cells and also in prevention of complications of high
cholesterol and reduction in formation of atherosclerosis pla-
que in hypercholesterolemia rat and rabbit.40
Data obtained from animal models of hepatic injury
showed that silymarin was capable of normalizing the
increase in plasma lipids following administration of carbon
tetrachloride and antagonizing the serum-free fatty acids
reduction induced by thioacetamide. In hepatic injury pro-
duced by paracetamol, silymarin improved low-density lipo-
protein binding to hepatocytes, which is a reliable factor for
the reduction of low-density lipoprotein in plasma. How-
ever, in an animal model of hepatic injury induced by thioa-
cetamide, silymarin was not able to normalize the reduction
in triglycerides in serum.25
The results of clinical research have also shown that sily-
marin can be introduced as a blood cholesterol reducer in
hypercholesterolemia patients. The daily use of silymarin in
420 mg dosage on 15 people with hypercholesterolemia led
to reduced cholesterol concentration in the gallbladder com-
pared with the control group, implying cholesterol synthesis
in the liver.41 Fourteen patients with type II hyperlipidemia
were clinically examined, as silymarin in 420 mg doses led
to reduced total blood cholesterol and increased high-density
lipoprotein cholesterol in patients.42
Renal Diseases
It has been reported that silybin present in the silymarin inhibits
renal toxicity resulting from administration of cisplatin in
laboratory mice. Moreover, silybin has inhibited renal disorders
resulting from the effect of cyclosporine in laboratory mouse.43
Recent studies have suggested that silymarin for kidney
health might be as important as for liver. Silymarin concentrates
in kidney cells and aids in regeneration of the cells by increasing
protein and nucleic acid synthesis. It has been suggested that
silymarin increases cell replication by 30%, which is related to
2 important components of silymarin: silybin and silychristin.
Silymarin has beneficial effects on diabetic nephropathy.44-46
It has been shown that silymarin might be effective for the pre-
vention of nephropathy-induced premature death in diabetic
patients. A study conducted on 60 diabetic patients with urinary
albumin excretion >300 mg/day showed that the silymarin-
treated group had 50% decrease in urine albumin–creatinine ratio
after 3 months of silymarin consumption. In most cases renal
impairments have been attributed to oxidative stress, inflamma-
tion, and fibrosis, and silymarin seems to act in these ways.
The potential effects of silymarin in diabetic nephropathy
have been shown in a few studies. It is also effective in prevent-
ing proteinuria in type 2 diabetes mellitus with overt nephropa-
thy. The effect of silymarin has mostly been related to its
antioxidant and anti-inflammatory effects.6,47 In this regard,
adding silymarin to renin–angiotensin system inhibitors in type
2 diabetic patients having proteinuria with overt nephropathy
could reduce malondialdehyde, urinary excretion of albumin,
and tumor necrosis factor-a.46,48
Nervous System
It has been reported that alcohol consumption may lead to
reduced learning ability in rats’ offspring. However, this effect
was prevented when it was co-administered with silymarin.
Inflammation of the nerves is the main cause of extensive nerve
cell damage. Moreover, silymarin can inhibit brain damage
caused by blockages in brain vessels.49 The influence of sily-
marin has been proved in the improvement of nerve conduction
of nerve fibers in patients with diabetes.50
Diabetes mellitus has been shown to reduce learning, mem-
ory, and cognitive skills, and administration of silymarin at
100 mg/kg dose enhanced the ability to store data in memory
and to recall it in diabetic rats. However, it does not improve
short-term spatial memory in diabetic rats. This beneficial
effects of silymarin has been attributed to attenuation of lipid
peroxidation in hippocampus tissue.51
Endocrine Gland
Results gained through study on animals suggest that silymarin
protects pancreas from chemical compounds including alloxan
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and cyclosporine. Sixty patients affected by alcoholic liver cir-
rhosis with insulin resistance diabetes were treated with sily-
marin. The outcome showed significant reduction in fasting
blood glucose, daily mean blood glucose level, glycosuria, and
insulin demand during 6 months.52
Hematologic Effects
One of the main properties of silymarin is antioxidant effects
on blood compounds. Oxidation of blood compounds was
found to be important in intensifying cardiovascular and other
chronic diseases. Based on laboratory reports, silymarin helps
prevent hemolysis of red blood cells induced by copper and
administration of hydrogen peroxide and other oxygen-
derived free radical producing materials.53
Immune System
Laboratory data indicate that silymarin has no effect on nonsti-
mulated neutrophils and chemotactic and phagocytic activities.
However, silymarin inhibits myeloperoxidase release when
neutrophils are evoked. Incubation of neutrophils with sily-
marin results in retardation of the function of leukocyte mobi-
lity inhibitors.
Treatment with silymarin led to increase in lectin as the sti-
mulator of lymphoblast deformation in a double-blind,
placebo-controlled trial on 40 patients with alcoholic liver cir-
rhosis. Besides, the number of T8þ cells dropped and lympho-
cytotoxicity suppressed significantly compared with that of the
control group.54
Anticancer Effects
Laboratory data show that silymarin and especially silybin pro-
duce chemopreventive effects on epidermal cancer cells, pros-
tate, as well as animal breast cancer.55 Silymarin showed
cytoprotective effects on cancer cells of prostate and human
breasts encountered with carcinogenic agents. Pre-inoculation
of cancer cells with silybin before exposure to silybin led to
increased Adriamycin effect in the prevention of cell growth.56
It should be noted that because of the strong antioxidant
effects of Silybum marianum, there is a concern that this plant
may produce interactions in fixing lymphocytotoxicity func-
tion of chemotherapy medicines acting through biochemical
peroxidative paths. However, silybin can strength cytotoxic
cisplatin and doxorubicin synergestic interactions, and there
is no evidence about its interaction with their cytotoxicity
effect.57
Data from animal studies emphasize that silymarin can pre-
vent carcinogenesis in epithelial tumors of different rat models.
For example, feeding rats with silymarin could protect them
against chemicals and UVB effects causing cancer.58
Stimulating effects of silymarin on liver DNA is exerted on
noncancerous cells. Silymarin in a study on hepatoma-bearing
rats did not stimulate tumor growth.59 Among studies in human
subjects, there is a report of a man with hepatocellular carcinoma
through biopsy proved to be unable to have surgery and then his
disease improved by taking daily 450 mg silymarin.
Osteoporosis
Taxifolin found in Silybum marianum has considerable estro-
genic properties. Additionally, flavonoid compounds in sily-
marin can affect metaphysis of femur without any connection
with B estrogenic receptors through exerting any estrogenic
agonist effect on the uterus.60
Psoriasis
Silymarin has been used traditionally to treat psoriasis. It may
act to improve psoriasis by removing unwanted metabolites
from body cells especially liver and also inhibiting cAMP cycle
and the synthesis of leukotrienes. There is a potential of
enhanced cAMP cycle and increased synthesis of leukotrienes
in patients with psoriasis that its inhibition by silymarin possi-
bly leads to improvements.61
Side Effects and Toxicities
Toxicity and Contraindications. Types of allergic reactions can
occur in people who are sensitive to natural products. An aller-
gic reaction to Silybum marianum has also been reported. There
is a report of an adverse reaction to Silybum marianum in an
English woman who seemingly had a capsule containing sev-
eral plant extracts. However, it is not obvious that to which
plant in the capsule the reaction was produced. Also a case
of anaphylaxis in a patient with a known allergy to the kiwi
fruit has been reported.62
Acute Toxicity. In animals, silymarin was found to have no sig-
nificant side effect even when administered at high doses.
Because of the stimulatory effects of the plant on the liver and
gallbladder, some experts believe that a mild laxative effect
may occur during earlier days of consumption. However, in a
randomized, controlled trial the side effects of this herb hardly
dominated the placebo. In a study of several thousand patients,
very low incidences of adverse effects were found, which
mainly were limited to mild gastrointestinal disorders.63
Chronic Toxicity. Long-term use of this herb is safe with no inci-
dence of abnormality. There is no report alluding to adverse
herb reactions during the course of a disease or in patients with
organ-specific disorder.64
Drug Interactions With Other Herbal or Chemical Medicines. Sily-
bum marianum can lower demand for insulin in diabetic
patients with alcohol-related liver cirrhosis. However, there is
no study about the effect of the herb on glucose metabolism
change in patients without liver disease.65
In a double-blind trial on 6 women patients who were
chronically using psychoactive drugs, the amount of liver
enzymes including alanine transaminase and aspartate
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transaminase were increased. Taking 400 mg silymarin twice
daily for 90 days led to decreased lipoperoxidase and liver
damage when compared with the control group.66
Silymarin can reduce adverse effect of chemical medicines
such as anticancer drugs including paclitaxel, cisplatin, meth-
othexate, fluorouracil, and blood lipid reducing drugs including
clofibrate, lovastatin, pravastatin, and psychoactive drugs like
haloperidol, tacrine, and some other medicines including nitrous
oxide, acetaminophen, metronidazole, and cyclosporine.67
Consumption During Breastfeeding and Pregnancy
Silybum marianum consumption during pregnancy, breastfeed-
ing, and also for children is permitted. Although the side effects
caused by plants in long term have not been proven during
pregnancy, during breastfeeding, and also for children, this
belief is considered based on long-term historical use as a food.
Consumption of this drug is suggested for the treatment of
pruritus associated with bile duct obstruction in pregnant
women. In addition, use of this herb in pregnant women leads
to inhibited liver damage. Administration is essential to preg-
nant women poisoned with Amanita mushroom.68
Dose
The doses of plant recommended here is the amount of commonly
administered doses of the herb rather than an applicable docu-
ment. However, doses are only determined for silymarin alone
and should be adjusted when combined with others. Furthermore,
they vary based on the type and severity of the condition of treat-
ment and even the patient’s individual characteristics.
In adults, reports of herb specialists suggest a range of doses.
The doses used in the literature ranged from 280 to 800 mg
daily silymarin. Most studies have applied concentrated stan-
dard product containing 70% to 80% silymarin. Standardized
plant extract dose is defined as 100 to 200 mg substance taken
orally twice a day with meals.64
In several studies, taking a 100 mg dose of Silybin co-
administered with phosphatidylcholine, 3 times daily, has been
introduced due to its higher reabsorption. In Europe, silybin
was injected intravenously at 20 to 50 mg/kg of body weight
dosage 3 or 4 times daily for the treatment of acute hepatotoxic
induced by Amanita poison.64
Tea is not a desirable method of administration because sily-
marin cannot dissolve in water well. But they can be used as her-
bal tea if seeds are crushed and fried. The usual dose is described
as 12 to 15 g fried and crushed grains, 3 times a day with meals.
The dose of tincture is 3 to 6 mL, 3 times daily with meal.9,69,70
Available standardized products should contain at least 70%
silymarin.3
Discussion
As already mentioned, silymarin or Silybum marianum has
been considered as a key for all diseases. It acts with various
mechanism; however, it is a very potent antioxidant and it
seems that the main mechanism of action of this plant is activ-
ity as a free radical scavenger and prevention of lipid peroxida-
tion. Silybum marianum has been shown to have some
additional mechanism by which it is able to protect liver, spe-
cifically. It increases the cellular glutathione in the liver, regu-
lates membrane permeability of liver cells, and increases their
membrane stability in the presence of xenobiotic damages, reg-
ulates nuclear expression by means of a steroid-like effect, and
inhibits the transformation of stellate hepatocytes into myofi-
broblasts, the one that is responsible for the deposition of col-
lagen fibers leading to cirrhosis.71 How it acts in other organs,
other than acting as an antioxidant, is not clear. Silymarin (and
especially silybin) is a powerful antioxidant and free radical
scavenger that restores a lot of internal antioxidants and pre-
vents oxidative stress.72
Oxidative stress has been shown to be implicated in a wide
range of pathological conditions such as chronic inflammation
and the generation of damage, particularly during ischemia/
reperfusion,73,74 neurological disorders,75,76 diabetes,77,78
atherosclerosis,79,80 cardiovascular diseases,81,82 cancer,83,84
gastrointestinal,85,86 and infectious,86-88 diseases or wound
complication.89,90 These conditions involve many changes
such as alterations in redox stat.91-94 Antioxidants possess the
ability to counteract these conditions.64,66,92
Various experimental and clinical investigations have
demonstrated promising results for the treatment and preven-
tion of life-threatening diseases with plants antioxidants.95-104
These agents are also effective in inhibition of toxic agents–
induced complications.105-110 Therefore, Silybum marianum
or silymarin, which is a powerful antioxidant and free radical
scavenger,4 should mainly act in this way in the prevention
of diseases and pathologic conditions.
Laboratory data associated with rats have shown that 2-
week remedy with silybin would protect them from
cyclosporine-induced lipid peroxidation.18 Silybin prevents
low-density lipoprotein from peroxidation in vitro and protects
human leukocytes against hydrogen peroxide, preventing DNA
damage.66 Silymarin also has antioxidant effects in human pla-
telets and acts as antioxidant in human liver and pulmonary
microsomes and consequently provide protective action against
induced lipid peroxidation with chemicals.66
Animal studies have shown that increased chronic iron over-
load leads to oxidation stress and liver damage and that sily-
marin can inhibit this toxicity by its antioxidant activity.111
Human studies have demonstrated that silymarin may
enhance superoxide dismutase in red blood cells and lympho-
cytes level in patients with alcoholic cirrhosis, thus increasing
antioxidant effects.26
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